Developing the Moderna COVID-19 Vaccine – A Personal Perspective

Featuring Brett Leav, A87, A23P

Location: Online

Date: March 11, 2021

Time: 12:00 pm to 1:30 pm

Cost: Free, but please register

You are cordially invited to a March 11 virtual lunchtime event with Brett Leav, A87, A23P, Vice President of Clinical Development, Public Health Vaccines at Moderna, Inc. Brett led the Clinical Trial team at Moderna that developed the Moderna COVID-19 vaccine in record time. Brett will discuss his path from Tufts to Moderna as well as his experience in leading the vaccine clinical trials.

Brett is a board-certified Infectious Disease specialist with over 10 years of experience in the clinical development of biological therapeutics to prevent and treat viral and bacterial diseases. He has overseen the clinical development of five different early stage biologicals from IND to BLA. 

Given the rapidly changing developments in the area of infectious diseases and the questions surrounding the efficacy of vaccines and other treatments, we are most grateful for Brett’s willingness to share his thoughts on these increasingly important subjects.

Please join us for what promises to be a very informative event. This event will be held via Zoom meeting. An audience Q&A session and networking in breakout rooms will follow Brett’s presentation.  This event will not be recorded.

More about the event:

This event is part of the Tufts Alumni Boston Business Leadership Series, which highlights Tufts alumni business leaders in the Boston area. Thank you to our Series host, Andy Merken, A87, of Burns & Levinson LLP. We look forward to “seeing” you there.